Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

VXRT Vaxart Inc

Price (delayed)

$0.5051

Market cap

$115.28M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.27

Enterprise value

$103.4M

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using tablets that can ...

Highlights
VXRT's gross profit has surged by 65% since the previous quarter
VXRT's revenue has surged by 65% since the previous quarter
VXRT's quick ratio has dropped by 78% year-on-year and by 16% since the previous quarter
The equity has contracted by 23% from the previous quarter and by 18% YoY

Key stats

What are the main financial stats of VXRT
Market
Shares outstanding
228.22M
Market cap
$115.28M
Enterprise value
$103.4M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.52
Price to sales (P/S)
2.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.18
Earnings
Revenue
$47.4M
Gross profit
$47.4M
Operating income
-$57.16M
Net income
-$58.12M
EBIT
-$57.81M
EBITDA
-$48.89M
Free cash flow
-$33.73M
Per share
EPS
-$0.27
EPS diluted
-$0.27
Free cash flow per share
-$0.15
Book value per share
$0.2
Revenue per share
$0.21
TBVPS
$0.66
Balance sheet
Total assets
$158.56M
Total liabilities
$112.94M
Debt
$16.83M
Equity
$45.62M
Working capital
-$35.86M
Liquidity
Debt to equity
0.37
Current ratio
0.64
Quick ratio
0.59
Net debt/EBITDA
0.24
Margins
EBITDA margin
-103.2%
Gross margin
100%
Net margin
-122.6%
Operating margin
-120.6%
Efficiency
Return on assets
-38.4%
Return on equity
-91.9%
Return on invested capital
-96.6%
Return on capital employed
-96.3%
Return on sales
-122%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

VXRT stock price

How has the Vaxart stock price performed over time
Intraday
18.99%
1 week
20.38%
1 month
44.77%
1 year
-50.48%
YTD
-23.71%
QTD
24.1%

Financial performance

How have Vaxart's revenue and profit performed over time
Revenue
$47.4M
Gross profit
$47.4M
Operating income
-$57.16M
Net income
-$58.12M
Gross margin
100%
Net margin
-122.6%
VXRT's net margin has soared by 87% YoY and by 47% QoQ
The operating margin has surged by 87% year-on-year and by 48% since the previous quarter
VXRT's gross profit has surged by 65% since the previous quarter
VXRT's revenue has surged by 65% since the previous quarter

Price vs fundamentals

How does VXRT's price correlate with its fundamentals

Growth

What is Vaxart's growth rate over time

Valuation

What is Vaxart stock price valuation
P/E
N/A
P/B
2.52
P/S
2.43
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
2.18
The EPS has increased by 49% year-on-year and by 18% since the previous quarter
The P/B is 32% below the 5-year quarterly average of 3.7 but 15% above the last 4 quarters average of 2.2
The equity has contracted by 23% from the previous quarter and by 18% YoY
VXRT's P/S is 99% below its 5-year quarterly average of 445.2 and 64% below its last 4 quarters average of 6.7
VXRT's revenue has surged by 65% since the previous quarter

Efficiency

How efficient is Vaxart business performance
The return on sales has surged by 87% year-on-year and by 48% since the previous quarter
The ROA has soared by 52% YoY and by 23% from the previous quarter
Vaxart's ROE has increased by 24% YoY and by 10% from the previous quarter
The company's return on invested capital rose by 23% YoY and by 7% QoQ

Dividends

What is VXRT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for VXRT.

Financial health

How did Vaxart financials performed over time
The company's total assets is 40% higher than its total liabilities
Vaxart's current ratio has shrunk by 80% YoY and by 15% QoQ
The company's total assets has surged by 79% YoY but it fell by 4.7% QoQ
VXRT's debt is 63% lower than its equity
Vaxart's debt to equity has increased by 23% QoQ and by 6% YoY
The equity has contracted by 23% from the previous quarter and by 18% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.